Regardless of these facts, the effect of higher concentrations of pronase E on RML infectivity was detrimental. not the sole, component of the transmissible prion[1]. It is proposed that PrPScis the infectious agent acting to replicate itself with high fidelity by recruiting endogenous PrPCand that the difference between these isoforms lies purely in the monomer conformation and its state of aggregation[1],[2],[5],[7],[8]. The distinct clinical and neuropathological phenotypes that distinguish prion strains are thought to be encoded by pathogenic PrP isoforms with divergent physicochemical properties[9][12]. PrPScis extracted from affected tissue as highly aggregated material Rucaparib (Camsylate) that is not amenable to high-resolution structural techniques. However, Fourier-transform infrared spectroscopic methods and hydrogen/deuterium exchange have shown that PrPSc, in sharp contrast to PrPC, has a high -sheet content[13][15]. PrPScis covalently Rucaparib (Camsylate) indistinguishable from PrPC[1],[7],[16]but can be differentiated from PrPCby its partial resistance to proteolysis and its marked insolubility in detergents[1],[7]. Under conditions in which PrPCexists as a detergent-soluble monomer and is completely degraded by the non-specific protease, proteinase K (PK), PrPScexists in Rucaparib (Camsylate) an aggregated form with the C-terminal two thirds of the protein showing marked resistance Rucaparib (Camsylate) to proteolytic degradation leading to the generation of amino-terminally truncated fragments of di-, mono- and non-glycosylated PrP[1],[7]. Although the molecular diagnosis of prion disease has historically relied upon the detection of PrPScusing PK, it has recently become apparent that PK-sensitive pathological isoforms of PrP may play an important role in the pathogenesis of prion diseases[17][27]. Accordingly, the development of new diagnostic tests that do not rely on PK digestion is essential to fully characterize human and animal prion diseases, and, in this context, the conformation-dependent immunoassay[17],[20]and the amyloid seeding assay[27],[28]both show higher diagnostic sensitivities than can be achieved using PK. Previously, using thermolysin and the mouse Rocky Mountain Laboratory (RML) prion strain, we demonstrated heterogeneity among PK-sensitive disease-related PrP isoforms and found that the majority of prion infectivity (80%) appeared to be associated with a minor fraction of PK-sensitive PrP[25]. Here we now report the development of a biochemical protocol which eliminates PrPCand the majority of brain proteins while preserving both PK-resistant and PK-sensitive prions. == Results == == Digestion with pronase E degrades PrPCand preserves RML prion titre == As part of ongoing research to identify proteases that offer alternatives to PK, we and others have previously shown that thermolysin can efficiently degrade PrPCwhile leaving disease-related PrP in full length form[25],[29],[30]. However despite the utility of thermolysin in certain diagnostic applications[25],[29],[30]the degradation of RML prion infectivity Rabbit Polyclonal to CSTL1 by thermolysin obviates its use for isolating PK-sensitive prions[25]. We have therefore continued to examine other proteases for their ability to degrade PrPCwhile preserving infectious prion titre. Of various proteases recently investigated, pronase E was found to be the most interesting. Representative digestions of uninfected CD-1 and RML prion-infected mouse brain homogenate with PK or pronase E are shown inFigure 1. Digestion with 50 g/ml PK at 37C for Rucaparib (Camsylate) 1 h completely degrades PrPCin 10% (w/v) normal CD-1 brain homogenate (Figure 1A) and in 10% (w/v) RML brain homogenate results in a change from a mixture of full-length and truncated PrP species to a characteristic pattern of amino-terminally truncated fragments of di-, mono- and non-glycosylated PrP derived from PrPSc(Figure 1A). In.